GSK and Sanofi shares could soar as pair start Covid-19 vaccine trials
Shares in the two pharmaceutical companies could soar in the months ahead as investors grow excited by the pair beginning coronavirus vaccine trials. But the WHO admits that vaccinations not expected until mid-2021.
- GlaxoSmithKline and Sanofi shares could soar as pair start Covid-19 vaccine trials
- WHO warns coronavirus vaccines won’t be widespread until mid-2021
- Race to find viable vaccine heats up among pharmaceutical companies
GlaxoSmithKline (GSK) and Sanofi could see their shares soar in the months ahead as investors grow excited by the pair beginning coronavirus vaccine trials. But the WHO admits that vaccinations are not expected until mid-2021.
The two pharmaceutical companies announced that they had begun the first phase of a two part clinical trial of their Covid-19 vaccine which will involve 440 participants in the US.
GSK is trading marginally lower on Friday at £14.70 per share, with the stock down 17% year-to-date, while Sanofi is also slightly down in today’s session and is down 7% since the start of the year.
GSK and Sanofi Phase 1 trial results expected in 2020
GSK and Sanofi said that they expect to finalise their first set of results from the trial in early December, with the intention of starting a Phase 3 trial later that month.
‘The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat Covid-19,’ Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, said.
‘Our dedicated teams and partner continue to work around the clock as we aim to deliver first results in early December. Positive data will enable a prompt start of the pivotal phase 3 trial by the end of this year,’ he added.
WHO says Covid-19 vaccinations not ready until mid-2021
Optimism is high due to the number of vaccinations going to trial at the moment, but the World Health Organisation (WHO) said that many will not be widespread until at least the middle of next year, with many checks required to test the effectiveness and viability of these vaccines.
‘We are really not expecting to see widespread vaccination until the middle of next year,’ WHO spokeswoman Margaret Harris said at a UN briefing in Geneva.
‘This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is,’ she added.
Race to find vaccine heats up
The race to find a vaccine is heating up, with AstraZeneca announcing earlier this week that it is holding advanced clinical trials for its own vaccine which it is developing in partnership with Oxford University.
The British-Swedish pharmaceutical company also said that it had struck a deal wit Oxford Biomedica to reserve production lines at the company's new manufacturing plant, after the UK government placing an order to 100 million doses of AstraZeneca’s vaccine.
As the moment there are approximately 160 vaccines being trialled around the world by companies, including Moderna, as well as a partnership between Pfizer and BioNTech.
How to trade stocks with IG
Looking to trade GlaxoSmithKline and other stocks? Open a live or demo account with IG and buy (long) or sell (short) shares using derivatives like CFDs in a few easy steps:
- Create an IG trading account or log in to your existing account
- Enter ‘GlaxoSmithKline’ in the search bar and select it
- Choose your position size
- Click on ‘buy’ or ‘sell’ in the deal ticket
- Confirm the trade
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.
